Skip Navigation

Radiation Protection Dosimetry 2004 111(1):115-119; doi:10.1093/rpd/nch372
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Al-Haj, A. N.
Right arrow Articles by Lagarde, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Haj, A. N.
Right arrow Articles by Lagarde, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Radiation Protection Dosimetry Vol. 111, No. 1 © Oxford University Press 2004; all rights reserved

Radiation dose profile in 125I brachytherapy: an 8-year review

A. N. Al-Haj*, A. M. Lobriguito and C. S. Lagarde

Biomedical Physics Department MBC 03, King Faisal Specialist Hospital & Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia

* Corresponding author: abdal{at}kfshrc.edu.sa

The use of episcleral plaques containing radioactive 125I seeds for brachytherapy treatment of selected retinoblastoma cases of patients is being done in Riyadh, Saudi Arabia since 1994. There are about three to four patients per year. A total of 31 patients were treated with a tumour dose in the range of 40–60 Gy using 8 seeds of 125I each from 1994 to 2002. This study determines the trend of occupational doses received by surgeons, anaesthesiologists and nurses and the dose rate profile around the eyes. Only 3% of the 275 persons monitored for Hp(10) have measurable doses with a weighted average of 4 µSv and 7% of the 175 persons monitored for Hp(0.07) have measurable doses with a weighted average of 0.3 mSv. The dose rate is maximum (110 µSv h–1) at the point of contact with the eye plaque and reduces to ~40% on the side of the other eye.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.